Claims
- 1. A substantially homogeneous, biologically active human lymphotoxin species comprising at least residues His+24 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II, which is unglycosylated.
- 2. The lymphotoxin of claim 1 having specific activity of about from 2.times.10.sup.7 units/mg to about 10.times.10.sup.7 units/mg of protein.
- 3. The lymphotoxin of claim 1 having a signal or leader polypeptide at the amino terminus of the lymphotoxin species.
- 4. The lymphotoxin of claim 1 comprising at least residues Leu+1 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II and having a methionyl or formyl methionyl group attached to residue Leu+1.
- 5. The lymphotoxin of claim 1 comprising at least residues Met-34 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II.
- 6. The lymphotoxin of claim 1 comprising at least residues Leu+1 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II.
- 7. The lymphotoxin of claim 6 in aggregate form.
- 8. The lymphotoxin of claim 1 having a methionyl or a formyl methionyl group attached to residue Kis+24.
- 9. The lymphotoxin of claim 1 in aggregate form.
- 10. The lymphotoxin of claim 1 wherein said lymphotoxin is the product of a prokaryotic expression system.
- 11. The lymphotoxin of claim 10 which is the product of an E. coli expression system.
- 12. A substantially homogeneous, biologically active lymphotoxin species consisting of residues His+24 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II, which is unglycosylated.
- 13. The lymphotoxin of claim 12 having a methionyl or a formyl methionyl group attached to residue His+24.
- 14. The lymphotoxin of claim 12 wherein said lymphotoxin is the product of a prokaryotic expression system.
- 15. The lymphotoxin of claim 14 which is the product of an E. coli expression system.
- 16. A substantially homogeneous, biologically active lymphotoxin species consisting of residues Leu+1 to Leu+171 of the amino acid sequence of FIGS. 2A-I and 2A-II, which is unglycosylated.
- 17. The lymphotoxin of claim 16 having a methionyl or a formyl methionyl group attached to residue Leu+1.
- 18. The lymphotoxin of claim 16 wherein said lymphotoxin is the product of a prokaryotic expression system.
- 19. The lymphotoxin of claim 18 which is the product of an E. coli expression system.
- 20. A therapeutic composition comprising the lymphotoxin of claim 1 or claim 12 and a physiologically acceptable stabilizer or excipient.
- 21. An article of manufacture comprising a vial which contains a composition according to claim 20 in sterile form.
- 22. A therapeutic composition comprising the lymphotoxin of claim 6 or claim 16 and a physiologically acceptable stabilizer or excipient.
- 23. An article of manufacture comprising a vial which contains a composition according to claim 22 in sterile form.
Parent Case Info
This is a divisional of prior application Ser. No. 06/732,312, filed 9 May 1985 and now abandoned, which is in turn a continuation-in-part of application Ser. No. 06/616,503, filed 31 May 1984, now abandoned. Reference is made to related application Ser. No. 06/608,316 entitled "Human Lymphotoxin", filed 7 May 1984 and now abandoned, and to application Ser. No. 06/616,502 entitled "Anti-Lymphotoxin", filed 31 May 1984, now U.S. Pat. No. 4,959,457.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
4481137 |
Ohnishi et al. |
Nov 1984 |
|
4703008 |
Lin |
Oct 1987 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
013828 |
Jun 1980 |
EPX |
Divisions (1)
|
Number |
Date |
Country |
Parent |
732312 |
May 1985 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
616503 |
May 1984 |
|